MimiVax Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 3


  • Latest Deal Type
  • Debt

  • Latest Deal Amount
  • $5.78M

  • Investors
  • 7

MimiVax General Information


Developer of immunotherapeutic vaccines and targeted therapies intended to control tumor growth and recurrence. The company's vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers, enabling healthcare providers to disrupt cancer, cure patients, and increase patient survival rates.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Corporate Office
  • Elm & Carlton Streets
  • Buffalo, NY 14263
  • United States
+1 (716) 000-0000

MimiVax Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MimiVax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Debt - General 12-Jul-2024 $5.78M 000.00 Completed Generating Revenue
8. Later Stage VC 09-Jan-2024 0000 Completed Generating Revenue
7. Later Stage VC 10-Dec-2021 000 0000 Completed Generating Revenue
6. Later Stage VC 24-Jun-2020 000 0000 Completed Clinical Trials - Phase 2
5. Later Stage VC 02-Aug-2019 0000 Cancelled Clinical Trials - Phase 2
4. Early Stage VC 000 000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 25-Aug-2015 00.000 000 Completed Startup
2. Grant 01-Mar-2015 $2M $450K Completed Startup
1. Seed Round 01-Jan-2012 $450K $450K Completed Startup
To view MimiVax’s complete valuation and funding history, request access »

MimiVax Executive Team (4)

Name Title Board Seat Contact Info
Michael Ciesielski Ph.D Co-Founder, Chief Executive Officer & President
Robert Fenstermaker MD Co-Founder & Chief Medical Officer
Anil Goyal Ph.D Chief Business Officer
Scott Friedman JD Co-Founder, General Counsel & Board Member
To view MimiVax’s complete executive team members history, request access »

MimiVax Board Members (5)

Name Representing Role Since
David Hohn MD Self Board Member 000 0000
Jeremy Jacobs Jr. Buffalo Capital Partners Chairman 000 0000
Michael Sexton JD Roswell Park Cancer Institute Board Member 000 0000
Scott Friedman JD Self Co-Founder, General Counsel & Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

MimiVax Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MimiVax Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
MEDA Angels Angel Group Minority 000 0000 000000 0
The Brain Tumor Investment Fund Not-For-Profit Venture Capital Minority 000 0000 000000 0
The Sontag Foundation Limited Partner Minority 000 0000 000000 0
Jerry Jacobs Angel (individual) Minority 000 0000 000000 0
Varia Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

MimiVax FAQs

  • When was MimiVax founded?

    MimiVax was founded in 2011.

  • Who is the founder of MimiVax?

    Michael Ciesielski Ph.D, Robert Fenstermaker MD, and Scott Friedman JD are the founders of MimiVax.

  • Who is the CEO of MimiVax?

    Michael Ciesielski Ph.D is the CEO of MimiVax.

  • Where is MimiVax headquartered?

    MimiVax is headquartered in Buffalo, NY.

  • What is the size of MimiVax?

    MimiVax has 3 total employees.

  • What industry is MimiVax in?

    MimiVax’s primary industry is Drug Discovery.

  • Is MimiVax a private or public company?

    MimiVax is a Private company.

  • What is MimiVax’s current revenue?

    The current revenue for MimiVax is 00000.

  • How much funding has MimiVax raised over time?

    MimiVax has raised $20.8M.

  • Who are MimiVax’s investors?

    MEDA Angels, The Brain Tumor Investment Fund, The Sontag Foundation, Jerry Jacobs, and Varia Ventures are 5 of 7 investors who have invested in MimiVax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »